This site is intended for healthcare professionals outside the US.

After VEGFR-TKI failure in aRCC,

Discontinuation due to side effects occurred in 13% of patients1

  • Management of severe and/or intolerable suspected adverse reactions may require dose reduction and/or temporary interruption of AFINITOR. Please view the Summary of Product Characteristics before prescribing
  • For adverse reactions of Grade 1, dose adjustment is usually not required. If dose reduction is required, the recommended dose is 5 mg daily and must not be lower than 5 mg daily
  • Table 1 of the Summary of Product Characteristics summarizes the dose adjustment recommendations for specific adverse reactions

AFINITOR—Low discontinuation rates across a range of adverse events1

AFINITOR - Low discontinuation rates across a range of adverse events
Reference:
  1. Motzer RJ, Escudier B, Oudard S, et al; for the RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.